Literature DB >> 17329985

Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians.

H Schelleman1, Z Chen, C Kealey, A S Whitehead, J Christie, M Price, C M Brensinger, C W Newcomb, C F Thorn, F F Samaha, S E Kimmel.   

Abstract

The objective of this study was to determine whether two vitamin K epoxide reductase complex 1 (VKORC1) polymorphisms contribute to the variability in warfarin response, particularly in African Americans. The effect of the VKORC1 1173C/T and -1639G/A polymorphisms was examined in a prospective cohort study of 338 warfarin users. Subjects carrying an 1173T allele had a lower warfarin maintenance dose compared with subjects with the CC genotype in African Americans (-12.10 mg/week+/-4.93; P=0.02) and Caucasians (-14.41 mg/week+/-3.28; P<0.001). Before reaching maintenance dose, only Caucasians with the T allele had significantly increased risk of international normalized ratio >3 (odds ratio=3.10; 95% confidence interval: 1.73-5.55) compared with Caucasians with the CC genotype. Polymorphisms in the VKORC1 gene are associated with warfarin maintenance dose requirements among both African Americans and Caucasians. However, these polymorphisms may not be as useful in predicting over-anticoagulation among African Americans.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17329985     DOI: 10.1038/sj.clpt.6100144

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  55 in total

1.  Genetic warfarin dosing: tables versus algorithms.

Authors:  Brian S Finkelman; Brian F Gage; Julie A Johnson; Colleen M Brensinger; Stephen E Kimmel
Journal:  J Am Coll Cardiol       Date:  2011-02-01       Impact factor: 24.094

2.  New genetic variant that might improve warfarin dose prediction in African Americans.

Authors:  Hedi Schelleman; Colleen M Brensinger; Jinbo Chen; Brian S Finkelman; Mark J Rieder; Stephen E Kimmel
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

3.  Practical Consideration of Genotype Imputation: Sample Size, Window Size, Reference Choice, and Untyped Rate.

Authors:  Boshao Zhang; Degui Zhi; Kui Zhang; Guimin Gao; Nita N Limdi; Nianjun Liu
Journal:  Stat Interface       Date:  2011       Impact factor: 0.582

4.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.

Authors:  Nihat Ozer; Nese Cam; Burak Tangurek; Songul Ozer; Huseyin Uyarel; Dilaver Oz; Mehmet Rasit Guney; Figen Ciloglu
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

5.  Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy.

Authors:  Chun Li; Ute I Schwarz; Marylyn D Ritchie; Dan M Roden; C Michael Stein; Daniel Kurnik
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

6.  VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.

Authors:  Fatima Donia Mili; Tenecia Allen; Paula Weinstein Wadell; W Craig Hooper; Christine De Staercke; Christopher J Bean; Cathy Lally; Harland Austin; Nanette K Wenger
Journal:  Future Cardiol       Date:  2017-12-08

7.  Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.

Authors:  N A Limdi; H Wiener; J A Goldstein; R T Acton; T M Beasley
Journal:  Blood Cells Mol Dis       Date:  2009-03-17       Impact factor: 3.039

8.  Laboratory and clinical outcomes of pharmacogenetic vs. clinical protocols for warfarin initiation in orthopedic patients.

Authors:  P A Lenzini; G R Grice; P E Milligan; M B Dowd; S Subherwal; E Deych; C S Eby; C R King; R M Porche-Sorbet; C V Murphy; R Marchand; E A Millican; R L Barrack; J C Clohisy; K Kronquist; S K Gatchel; B F Gage
Journal:  J Thromb Haemost       Date:  2008-07-24       Impact factor: 5.824

Review 9.  Warfarin sensitivity genotyping: a review of the literature and summary of patient experience.

Authors:  Thomas P Moyer; Dennis J O'Kane; Linnea M Baudhuin; Carmen L Wiley; Alexandre Fortini; Pamela K Fisher; Denise M Dupras; Rajeev Chaudhry; Prabin Thapa; Alan R Zinsmeister; John A Heit
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

10.  VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.

Authors:  Nita A Limdi; T Mark Beasley; Michael R Crowley; Joyce A Goldstein; Mark J Rieder; David A Flockhart; Donna K Arnett; Ronald T Acton; Nianjun Liu
Journal:  Pharmacogenomics       Date:  2008-10       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.